Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis
ConditionPrurigo Nodularis (PN)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUMC Utrecht
About this trial
With the arrival of dupilumab as the first available targeted therapy for PN, there is an unmet need for real-world data and translational research on the working mechanism of dupilumab on PN, to optimize individualized targeted treatment.
Eligibility criteria
Qualifiers
Adult patients with moderate-to-severe prurigo nodularis starting dupilumab treatment
Disqualifiers
Unwilling to participate in the BioDay registry
(For translational endpoints only) Unwilling to participate in UMC Utrecht Biobank
Trial design
Treatments tested in this trial
- Dupilumab
Treatment groups
No treatment groups listed
Sponsors and collaborators
UMC Utrecht
Lead sponsor
Sanofi
Collaborator
Source ClinicalTrials.gov